Farther Finance Advisors’s Citius Oncology CTOR Stock Holding History

Farther Finance Advisors’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3	Closed	-$3	–	5923
2025 Q4	$3	Hold	3	–	–	﹤0.01%	5439
2025 Q3	$6	Buy	+3	New	+$6	﹤0.01%	4933

Other funds holding CTOR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Farther Finance Advisors's CTOR Position: Q1 2026 in Review

Farther Finance Advisors sold out of Citius Oncology (CTOR) in Q1 2026, closing a stake of 3 shares — an estimated $3 sold.

Farther Finance Advisors first reported a position in CTOR in Q3 2025 and held it in 2 quarters. The position peaked at $6 in Q3 2025. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

Farther Finance Advisors reported no remaining Citius Oncology position as of Q1 2026 after selling out during the quarter.
Farther Finance Advisors sold 3 Citius Oncology shares in Q1 2026, an estimated $3.
Farther Finance Advisors first reported a position in Citius Oncology in Q3 2025 and held it in 2 quarters.
Farther Finance Advisors's Citius Oncology position peaked at $6 in Q3 2025.
14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.